Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insmed (INSM)

Abrocitinib, a drug by Pfizer, showed sustained improvement in skin clearance and itch reduction for 112 weeks in patients with moderate or severe atopic dermatitis (AD), according to a post hoc analysis of two phase 3 trials. The study found that both 100 mg and 200 mg doses maintained efficacy, with no unexpected safety signals. Pfizer sponsored the research, and some authors have ties to the company.

The EMA expressed concerns over the Patina trial results, leading Pfizer to withdraw its Ibrance application for a specific indication. The EMA questioned potential bias in the results. A medical oncologist noted differing regulatory approaches between the EMA and FDA, which approved the indication based on the same trial data.

The European Commission approved a combination of Merck's Keytruda and Pfizer/Astellas' Padcev for treating muscle-invasive bladder cancer. This is the first such approval in Europe for a PD-1 inhibitor. According to the companies, the regimen is intended for resectable cases.

The EMA's CHMP declined to extend Pfizer's Mylotarg (gemtuzumab ozogamicin) for children with newly diagnosed AML, citing insufficient evidence of effectiveness. The drug is currently approved for adults with AML. The agency will update the product information with pediatric data. The decision does not affect Mylotarg's existing approval for patients aged 15 years or older.

The FDA approved Seagen's (Pfizer subsidiary) tucatinib (Tukysa) for HER2-positive breast cancer maintenance treatment, showing 24.9 months PFS vs. 16.3 months with placebo. Pharmacists must monitor for hepatotoxicity and manage side effects.

Pfizer (PFE) stock rose 2.2% to $30.09, hitting a 52-week high of $30.23 after positive clinical trial data for its elranatamab drug. JP Morgan raised its price target to $30, while Guggenheim maintains a Buy rating with a $31 target. The stock has gained 27% from its 52-week low. Broader market trends and upcoming earnings also contributed to the move.